Trials / Completed
CompletedNCT00305929
Study of WST09 in Prostate Cancer After Radiation: Repeat Procedure
Phase II Study of Photodynamic Therapy With WST09 in Patients With Recurrent or Persistent Localized Carcinoma of the Prostate Following Radiation Therapy Failure - Repeat Procedure
- Status
- Completed
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 8 (estimated)
- Sponsor
- STEBA France · Industry
- Sex
- Male
- Age
- —
- Healthy volunteers
- Not accepted
Summary
This is a multi-centre, phase II, open-label, 12-month clinical trial for patients previously treated with WST09 (Tookad) who have positive prostate biopsies for cancer. The study aims at delivering a second WST09 treatment for the purpose of eradicating the localized prostate cancer.
Detailed description
Multi-centre, phase II, open-label, 12-month clinical trial for patients that previously received a vascular-targeted photodynamic treatment (VTP) with WST09 (Tookad) and still have histological findings (prostate biopsies) indicating the presence of localized cancer. The WST09-mediated VTP procedure consists of an I.V. infusion of WST09 (Tookad) at 2 mg/kg, in combination with the per-cutaneous interstitial delivery of monochromatic laser light (of a wavelength of 763nm) via the trans-perineal implantation of illumination fibres, positioned in the prostatic lobes. In a previous Tookad trial, escalating doses of laser light were used with a fixed dose of WST09 (2 mg/kg) in patients with localized prostatic cancer. Patients who underwent the procedure but still have positive prostate biopsies (residual cancer) may benefit from an additional WTS09-mediated VTP procedure. Thus, the aim of this study is to treat patients still presenting with localized prostate cancer with a second WST09-mediated VTP procedure.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Treatment with Tookad VTP | |
| DRUG | Treatment with Tookad VTP | Tookad 2 mg/kg |
| DRUG | Treatment with Tookad VTP | 2 mg/kg |
Timeline
- Start date
- 2006-03-01
- Completion
- 2007-12-01
- First posted
- 2006-03-22
- Last updated
- 2010-06-02
Locations
1 site across 1 country: Canada
Source: ClinicalTrials.gov record NCT00305929. Inclusion in this directory is not an endorsement.